|The purpose of this research study is to test the safety and effectiveness of the investigational drug EVP-6124 in the treatment of subjects with mild to moderate dementia due to Alzheimer's disease.|
|About the Study|
Alzheimer's disease (AD) is the leading cause of dementia in the elderly. The prevalence of dementia in those ≥65 years in North America is approximately 6 to 10%, with AD accounting for approximately 66% of these cases. This illness represents a steadily growing medical and social problem of our aging societies.
The EVAD study is designed to provide additional evidence of the safety, tolerability, and cognitive effects of EVP-6124 in subjects with mild to moderate dementia due to AD currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor (AChEI) (donepezil, rivastigmine, or galantamine).
Number of visits:
Eligible participants will be assigned by chance to one of the following treatment groups:
|Up to 34 weeks|
|If you are interested in volunteering for this trial, call the Institute for Dementia Research and Prevention at 225-763-2973 or email firstname.lastname@example.org.|